Developer docs
API playgroundTry for free, no card

Search company profiles

Anagenex

Full company profile

uuid0000ma5

Namestring
Anagenex
Websiteurl
anagenex.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Anagenex is a privately held biotechnology company founded in 2019 and headquartered in Lexington, Massachusetts, operating an ML-driven drug discovery platform focused on small molecule therapeutics against difficult targets. The company's core technology pairs large-scale experimental data generation with machine learning models, creating an integrated wet-lab-and-compute loop that the company describes as a novel method architecture distinguishing it from purely computational or purely empirical drug discovery approaches. Use of Series A proceeds explicitly targets both expansion of the data-generating platform and advancement of new drug programs, indicating the company is building internal pipeline assets alongside its platform offering.

Anagenex pursues a B2B go-to-market motion targeting pharmaceutical companies through drug discovery partnerships and platform licensing arrangements. Commercial terms are not publicly disclosed, and pricing is negotiated deal-by-deal. The company is supported by a high-quality investor syndicate including Catalio Capital Management (Series A lead), Lux Capital, Khosla Ventures, Air Street Capital, Menlo Ventures, Obvious Ventures, and Expeditions, with $37.2 million in disclosed funding across a January 2020 round and a June 2022 Series A. Leadership comprises CEO Nicolas Tilmans and CTO Adrian Schreyer; the company maintains a headcount in the 11–50 range. No named customers, revenue figures, or commercial milestones are disclosed in the available source material, consistent with an early-stage platform company pre-commercial scale or in the early stages of partnership-based monetization.

Short descriptiontext

Anagenex is a privately held Lexington, Massachusetts biotech using a proprietary ML-driven, large-scale data-generation platform to discover small molecule drugs against difficult targets, serving pharmaceutical companies through B2B partnerships and licensing deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
drug discovery platform, small molecule therapeutics, machine learning biotechnology, pharmaceutical partnerships, target identification
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAABAL
AutoML & Low-Code ML Platform Operations
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/ML Platforms, MLOps & Model Lifecycle Management
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-Driven Drug Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Discovery Platform Services
TypeLicensing Royalties
Description

Revenue generated through drug discovery partnerships and platform licensing arrangements with pharmaceutical companies. The company develops new drug programs using its ML platform and likely commercializes these through partnerships or out-licensing deals with major pharmaceutical companies.

finsmes.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Anagenex operates an ML-driven drug discovery platform that pairs large-scale experimental data generation with machine learning to advance small molecule therapeutic programs against difficult targets. The company develops proprietary datasets and ML models and commercializes its capabilities through drug discovery partnerships and licensing arrangements with pharmaceutical companies rather than selling discrete software products.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Anagenex is a biotechnology company that operates a data-generating platform for small molecule drug discovery. The company combines large-scale data generation with machine learning to advance drug programs. Based on the available sources, no specific named products, modules, or sub-brands were identified — the company appears to offer its platform as a unified offering rather than as discrete named products.

Product and service1 record
1ML-Driven Drug Discovery Platform
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recursion operates a high-throughput experimental biology platform combined with ML to map biology and discover new therapeutics. It is a direct competitor in combining large-scale data generation with ML for drug discovery, with substantially more capital and clinical-stage programs.

2Isomorphic Labs
TypeDirect peer
Description

Isomorphic Labs, an Alphabet subsidiary, applies DeepMind's AI to drug discovery with a focus on difficult targets and pharma partnerships. It is a direct competitor with substantially greater resources and AI capabilities targeting the same difficult-target niche.

TypeDirect peer
Description

Atomwise applies AI and structure-based design to small molecule drug discovery, partnering with pharma and academic groups. It is a direct peer in the AI small molecule discovery space, particularly for difficult targets.

TypeEmerging player
Description

Lantern Pharma is an AI-driven oncology drug development company using ML to identify responders and repurpose/develop therapeutics. It overlaps with Anagenex in applying AI to small molecule drug discovery, with a narrower therapeutic focus.

TypeDirect peer
Description

Exscientia is an AI-driven drug design company focused on small molecule discovery through computational chemistry and active learning. It directly competes with Anagenex in AI-enabled small molecule drug discovery and pharma partnerships.

TypeDirect peer
Description

Insitro is a machine learning-driven drug discovery company combining high-throughput biology with ML to develop therapeutics. It directly competes with Anagenex in the AI-enabled small molecule and target discovery space serving pharma partners.

TypeEmerging player
Description

Generate Biomedicines is an ML-driven generative biology platform creating novel protein therapeutics. It overlaps with Anagenex in applying generative AI to therapeutic discovery, though focused on biologics rather than small molecules.

TypeEmerging player
Description

BenchSci applies AI to accelerate life science research and preclinical drug discovery, helping scientists select experimental reagents and design experiments. It is an adjacent emerging player that uses ML to improve wet-lab productivity for drug discovery teams.

TypeDirect peer
Description

Schrödinger provides computational chemistry and physics-based simulation platforms used for small molecule drug discovery across pharma. It is a direct competitor with a more mature software platform serving the same pharma R&D customers as Anagenex.

TypeEmerging player
Description

Cradle applies ML to protein engineering and design. It is a comparable emerging player using ML-driven approaches for therapeutic discovery, though focused on protein design rather than small molecule hit identification.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anagenex

AI-Driven Drug Discovery Platformanagenex.com

Anagenex is a privately held Lexington, Massachusetts biotech using a proprietary ML-driven, large-scale data-generation platform to discover small molecule drugs against difficult targets, serving pharmaceutical companies through B2B partnerships and licensing deals.

What Anagenex does

Anagenex is a privately held biotechnology company founded in 2019 and headquartered in Lexington, Massachusetts, operating an ML-driven drug discovery platform focused on small molecule therapeutics against difficult targets. The company's core technology pairs large-scale experimental data generation with machine learning models, creating an integrated wet-lab-and-compute loop that the company describes as a novel method architecture distinguishing it from purely computational or purely empirical drug discovery approaches. Use of Series A proceeds explicitly targets both expansion of the data-generating platform and advancement of new drug programs, indicating the company is building internal pipeline assets alongside its platform offering.

Anagenex pursues a B2B go-to-market motion targeting pharmaceutical companies through drug discovery partnerships and platform licensing arrangements. Commercial terms are not publicly disclosed, and pricing is negotiated deal-by-deal. The company is supported by a high-quality investor syndicate including Catalio Capital Management (Series A lead), Lux Capital, Khosla Ventures, Air Street Capital, Menlo Ventures, Obvious Ventures, and Expeditions, with $37.2 million in disclosed funding across a January 2020 round and a June 2022 Series A. Leadership comprises CEO Nicolas Tilmans and CTO Adrian Schreyer; the company maintains a headcount in the 11–50 range. No named customers, revenue figures, or commercial milestones are disclosed in the available source material, consistent with an early-stage platform company pre-commercial scale or in the early stages of partnership-based monetization.

Anagenex firmographics

Firmographics
Name
Anagenex
Website
https://anagenex.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Anagenex is a privately held Lexington, Massachusetts biotech using a proprietary ML-driven, large-scale data-generation platform to discover small molecule drugs against difficult targets, serving pharmaceutical companies through B2B partnerships and licensing deals.
Ownership category
akta.pro rank

Anagenex industry classification

Industry
Product category
AI-Driven Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAABAL
AutoML & Low-Code ML Platform Operations
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/ML Platforms, MLOps & Model Lifecycle Management

Keywords

  • Drug discovery platform
  • Small molecule therapeutics
  • Machine learning biotechnology
  • Pharmaceutical partnerships
  • Target identification

Where Anagenex is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Markets served

Anagenex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Drug Discovery Platform Services: Revenue generated through drug discovery partnerships and platform licensing arrangements with pharmaceutical companies. The company develops new drug programs using its ML platform and likely commercializes these through partnerships or out-licensing deals with major pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Anagenex product offering

Product offering

Core offering

Anagenex operates an ML-driven drug discovery platform that pairs large-scale experimental data generation with machine learning to advance small molecule therapeutic programs against difficult targets. The company develops proprietary datasets and ML models and commercializes its capabilities through drug discovery partnerships and licensing arrangements with pharmaceutical companies rather than selling discrete software products.

Product overview

Anagenex is a biotechnology company that operates a data-generating platform for small molecule drug discovery. The company combines large-scale data generation with machine learning to advance drug programs. Based on the available sources, no specific named products, modules, or sub-brands were identified — the company appears to offer its platform as a unified offering rather than as discrete named products.

Differentiator

Problem solved

Functional benefit

Products and services

  • ML-Driven Drug Discovery Platform

Companies that use Anagenex

Customer profile

Segments1 record

Ideal customer profiles1 record

Anagenex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Anagenex partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Anagenex competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Recursion operates a high-throughput experimental biology platform combined with ML to map biology and discover new therapeutics. It is a direct competitor in combining large-scale data generation with ML for drug discovery, with substantially more capital and clinical-stage programs.
  • Isomorphic Labs: Isomorphic Labs, an Alphabet subsidiary, applies DeepMind's AI to drug discovery with a focus on difficult targets and pharma partnerships. It is a direct competitor with substantially greater resources and AI capabilities targeting the same difficult-target niche.
  • Atomwise: Atomwise applies AI and structure-based design to small molecule drug discovery, partnering with pharma and academic groups. It is a direct peer in the AI small molecule discovery space, particularly for difficult targets.
  • Exscientia: Exscientia is an AI-driven drug design company focused on small molecule discovery through computational chemistry and active learning. It directly competes with Anagenex in AI-enabled small molecule drug discovery and pharma partnerships.
  • Insitro: Insitro is a machine learning-driven drug discovery company combining high-throughput biology with ML to develop therapeutics. It directly competes with Anagenex in the AI-enabled small molecule and target discovery space serving pharma partners.
  • Schrödinger: Schrödinger provides computational chemistry and physics-based simulation platforms used for small molecule drug discovery across pharma. It is a direct competitor with a more mature software platform serving the same pharma R&D customers as Anagenex.

Emerging players

  • Lantern Pharma: Lantern Pharma is an AI-driven oncology drug development company using ML to identify responders and repurpose/develop therapeutics. It overlaps with Anagenex in applying AI to small molecule drug discovery, with a narrower therapeutic focus.
  • Generate Biomedicines: Generate Biomedicines is an ML-driven generative biology platform creating novel protein therapeutics. It overlaps with Anagenex in applying generative AI to therapeutic discovery, though focused on biologics rather than small molecules.
  • BenchSci: BenchSci applies AI to accelerate life science research and preclinical drug discovery, helping scientists select experimental reagents and design experiments. It is an adjacent emerging player that uses ML to improve wet-lab productivity for drug discovery teams.
  • Cradle Bio: Cradle applies ML to protein engineering and design. It is a comparable emerging player using ML-driven approaches for therapeutic discovery, though focused on protein design rather than small molecule hit identification.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Anagenex social profiles

Digital presence

Anagenex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anagenex leadership team

Management profile

Number of profiles

Profiles2 records

Anagenex funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anagenex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anagenex

What does Anagenex do?

Anagenex operates an ML-driven drug discovery platform that pairs large-scale experimental data generation with machine learning to advance small molecule therapeutic programs against difficult targets. The company develops proprietary datasets and ML models and commercializes its capabilities through drug discovery partnerships and licensing arrangements with pharmaceutical companies rather than selling discrete software products.

Is Anagenex a public or private company?

Anagenex is a private company. It is classified as venture growth investor backed and is currently operating.

When was Anagenex founded?

Anagenex was founded in 2019. It employs 1 to 10 people.

Where is Anagenex based?

Anagenex is headquartered in Lexington, United States, in the North America region.

How does Anagenex make money?

One revenue line is on record: drug Discovery Platform Services.

Who are Anagenex's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Isomorphic Labs, Atomwise, Exscientia, Insitro and Schrödinger. Emerging players are Lantern Pharma, Generate Biomedicines, BenchSci and Cradle Bio.

Does Anagenex have an API?

No public API is recorded for Anagenex.

What industry is Anagenex in?

Anagenex's product category is AI-Driven Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAAABAL, AutoML & Low-Code ML Platform Operations. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAnagenex Announces First Programs in Synthetic Lethal Oncology FranchiseAnagenex announced its first two preclinical synthetic lethal oncology programs targeting PRMT5 and MAT2A, leveraging MTAP deletion in 15% of solid tumors. The company plans to nominate one program as a development candidate in 2H 2025, with expansion into immunology in 2024.Business Wire BlogAnagenex Expands Leadership Team with Appointment of Adrian Schreyer, Ph.D., as Chief Technology OfficerAnagenex appointed Adrian Schreyer, Ph.D., as Chief Technology Officer. He previously led AI drug discovery at Exscientia, where he built its AI team and supported a successful IPO. The appointment follows a multi-target collaboration with Nimbus Therapeutics.Business Wire BlogAnagenex Expands Leadership Team with Appointment of Adrian Schreyer, Ph.D., as Chief Technology OfficerAnagenex appointed Adrian Schreyer, Ph.D., as Chief Technology Officer. He previously served as CTO at Exscientia, where he built its AI drug discovery platform. The appointment follows a multi-target collaboration with Nimbus Therapeutics.Business Wire BlogAnagenex Strengthens Board of Directors with Appointments of Robert Forrester and Isaac RoAnagenex appointed Robert Forrester as Executive Chairman and Isaac Ro to its Board of Directors. The company's AI-driven platform has powered two lead programs, and the appointments aim to expand its pipeline and partnerships.Business Wire BlogAnagenex Closes $30 Million Series A Round led by Catalio to Advance Small Molecule Drug Discovery with a Novel, Directed Evolution PlatformAnagenex closed a $30 million Series A round led by Catalio Capital Management, with participation from existing investors. The company will use the funds to expand its directed evolution platform and build a pipeline for unmet medical needs. The platform has processed over 25 targets and identified active compounds for eight.Business Wire BlogAnagenex Closes $30 Million Series A Round led by Catalio to Advance Small Molecule Drug Discovery with a Novel, Directed Evolution PlatformAnagenex has closed a $30 million Series A financing round led by Catalio Capital Management, with participation from existing investors Lux Capital, Khosla Ventures, Obvious Ventures, Air Street Capital, and Menlo Ventures. The company will utilize these funds to expand its novel data-generating platform for small molecule drug discovery and build a pipeline of programs addressing unmet medical needs. Since its inception, Anagenex has raised a total of $37.2 million and has already identified biochemically active compounds for eight targets using its directed evolution technology.FinSMEsAnagenex Raises $30M in Series A FundingAnagenex, a drug discovery company focused on small molecule medicines, closed a $30 million Series A financing round led by Catalio Capital Management, with participation from several other investors. The funding will be used to expand its data generating platform and advance its drug discovery pipeline. Anagenex has now raised a total of $37.2 million in financing to date.BioSpaceAnagenex Closes $30 Million Series A Round led by Catalio to Advance Small Molecule Drug Discovery with a Novel, Directed Evolution PlatformAnagenex closed a $30 million Series A financing round led by Catalio Capital Management, with participation from Lux Capital, Khosla Ventures, Obvious Ventures, Air Street Capital, and Menlo Ventures. The company intends to use the funds to expand its directed evolution platform for small molecule drug discovery and build a pipeline of programs addressing unmet medical needs. Since its inception, Anagenex has raised a total of $37.2 million and has identified biochemically active compounds for eight targets, including an undruggable target.Venture Capital Access OnlineAnagenex Closes $30 Million Series A Round led by Catalio to Advance Small Molecule Drug Discovery with a Novel, Directed Evolution PlatformAnagenex has successfully closed a $30 million Series A financing round led by Catalio Capital Management to enhance its small molecule drug discovery platform. The funding will help the company expand its innovative data-generating platform and build a pipeline of programs targeting challenging medical needs. Anagenex has already identified promising compounds for multiple drug targets since its inception in 2020.VC News DailyAnagenex Closes $30M Series A RoundAnagenex, a San Francisco-based drug discovery company, has closed a $30 million Series A financing round led by Catalio Capital Management, with participation from existing investors Lux Capital, Khosla Ventures, Obvious Ventures, Air Street Capital, and Menlo Ventures. The funding will support the company's pre-clinical small molecule drug discovery efforts through its machine learning-driven directed evolution platform. The company maintains offices in the San Francisco Bay area and Woburn, Massachusetts.